|Mr. Alexis Borisy||Co-Founder, Founding Advisor & Independent Director||114k||N/A||1972|
|Mr. Troy Cox||CEO, Pres & Director||N/A||N/A||1964|
|Mr. Jason Ryan||CFO & Principal Accounting Officer||N/A||N/A||1974|
|Mr. Konstantin Fiedler||Chief Operating Officer||N/A||N/A||1966|
|Mr. Tom Godden||Chief Information Officer||N/A||N/A||N/A|
Foundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with F. Hoffmann-La Roche Ltd.; and Genentech, Inc. Foundation Medicine, Inc. has a collaboration with The European Organisation for Research and Treatment of Cancer to advance precision medicine using comprehensive genomic profiling to facilitate clinical trial enrollment. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc.
Foundation Medicine, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 9. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 5; Compensation: 8.